Global mRNA Synthesis & Manufacturing Market Outlook
Revenue, 2024
$2.1B
Forecast, 2034
$3.9B
CAGR, 2025 - 2034
6.2%
The mRNA Synthesis & Manufacturing industry revenue is expected to be around $2.3 billion in 2025 and expected to showcase growth with 6.2% CAGR between 2025 and 2034. mRNA production and processing have become a game changer, in the field of biotechnology with uses such as in vaccines and gene therapy applications. The market for production and processing was worth USD 2.1 billion in 2024 and is projected to see substantial growth to reach USD 3.1 billion by 2030 and USD 4.1 billion by 2035 due, to a compound growth rate of around 6.2%.
The production and creation of mRNA play a role, in the field of biotechnology as a whole. Given its ability to scale efficiently and accurately while being bio-compatible mRNA technology provides an powerful foundation for developing therapies and vaccines. This innovative approach allows cells to generate proteins that have the potential to combat or stop illnesses such as cancer, inherited conditions and infectious ailments
Market Key Insights
- The mRNA Synthesis & Manufacturing market is projected to grow from $2.1 billion in 2024 to $3.9 billion in 2034. This represents a CAGR of 6.2%, reflecting rising demand across Vaccines, Cancer Immunotherapy and Gene Editing .
- Thermo Fisher Scientific Inc., Danaher, Merck KGaA are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the mRNA Synthesis & Manufacturing market and are expected to observe the growth CAGR of 4.0% to 6.0% between 2024 and 2030.
- Emerging markets including India, South Korea and Brazil are expected to observe highest growth with CAGR ranging between 7.1% to 8.6%.
- Transition like Precision Medicine has greater influence in United States and Germany market's value chain; and is expected to add $85 million of additional value to Mrna Synthesis & Manufacturing industry revenue by 2030.
- The mRNA Synthesis & Manufacturing market is set to add $1.8 billion between 2024 and 2034, with manufacturer targeting Academic & Research Institutions & CROs End-User projected to gain a larger market share.
- With Vaccination demand, and Personalized medicine, mRNA Synthesis & Manufacturing market to expand 82% between 2024 and 2034.
Opportunities in the mRNA Synthesis & Manufacturing
The driven advancements of Novel mRNA in editing offers possibilities for treating diseases
Growth Opportunities in North America and Asia-Pacific
In North America MRNA Synthesis & Manufacturing market is thriving due to its research environment and presence of established pharmaceutical companies that have been quick to adopt mRNA vaccines in the face of the COVID pandemic. Key industry players such as Moderna and Pfizer have established themselves as leaders in the region by utilizing cutting edge Synthesizing technologies and securing contracts.The higher pricing, in this region is a reflection of the demand and specialized manufacturing skills here.In North Americas business environment is fiercely competitive with investments in research and development enabling companies to uphold their leading positions in the market landscape. This trend is predicted to fuel growth as companies venture into new mRNA applications
The Asia Pacific region is becoming a developing area, in the MRNA Synthesis & Manufacturing market as countries such as China, South Korea and India are investing more in biotechnology and healthcare infrastructure. The presence of companies like Samsung Biologics in the market forming partnerships strategically to enhance regional manufacturing capabilities. Despite this growth pricing continues to be more competitive than in North America with an emphasis placed on making treatments affordable and accessible.With the focus on cost effectiveness, in the Asia Pacific area is driving growth opportunities as various manufacturers enhance their production capacities to meet both domestic & global demand
Market Dynamics and Supply Chain
01
Driver: Vaccination Demand, and Technological Innovations
The rising necessity for vaccine creation in response to infectious diseases is also leading to a growing requirement, for expandable mRNA technologies Progress in using lipid nanoparticle delivery systems is also improving the effectiveness of mRNA treatments and supporting development in research and commercial use
The increasing focus on personalized treatments in the field of oncology is also driving the advancement of tailored mRNA based therapies
02
Restraint: Manufacturing Complexity
The unique complexity of manufacturing mRNA poses obstacles when trying to expand production and adhere to guidelines
03
Opportunity: Global Vaccine Development and Oncology Breakthroughs
Governments are focusing more on preparing for pandemics. There is an increasing need for mRNA technologies to develop vaccines in short development time
Exploring the potential of mRNA, in cancer immunotherapy presents market prospects for companies specializing in precision medicine
04
Challenge: High Production Costs
The widespread use of mRNA is restricted by the expenses associated with materials and the strict quality standards needed for production. This poses a challenge for its adoption in emerging markets
Supply Chain Landscape
1
Raw Material Suppliers
NucleotidesEnzymes
2
mRNA Synthesizers
Pharmaceutical CompaniesContract Manufacturers
3
Packaging & Distribution Partners
4
End-User
HealthcareBiotechResearch Institutions
1
Raw Material Suppliers
NucleotidesEnzymes
2
mRNA Synthesizers
Pharmaceutical CompaniesContract Manufacturers
3
Packaging & Distribution Partners
4
End-User
HealthcareBiotechResearch Institutions
Use Cases of mRNA Synthesis & Manufacturing in Vaccines & Cancer Immunotherapy
Vaccines : The swift progress and triumph of mRNA vaccines, in the context of the COVID 19 crisis have clearly demonstrated their effectiveness in delivering adaptable solutions to combat illnesses. Pioneering companies such as Pfizer and Moderna utilize mRNAs capacity to provoke responses promptly
Cancer Immunotherapy : Vaccines, for cancer that are based on mRNA are a focus of healthcare as they aim to target specific mutations in tumors effectively. BioNTech is at the forefront of creating vaccines that help the body's immune system fight against cancer cells—a step forward, in treating cancer
Gene Editing : Researchers can leverage mRNA in CRISPR driven gene editing to ensure manipulation of genes, for addressing mutations effectively and with accuracy. Companies like CRISPR Therapeutics and Editas Medicine are, at the forefront of advancing mRNA based tools to enhance the efficiency and specificity of gene therapy applications
Rare Diseases : Medications aiming to treat illnesses like the ones, in progress at Arcturus Therapeutics are utilizing mRNA technology to present therapeutic possibilities for ailments that were once, beyond treatment options. This showcases the nature and potential of mRNA platforms
Recent Developments
These advancements indicate decisions made by leading companies to increase production capabilities and enter markets geographically
July 2023 : Arcturus Therapeutics has started conducting Phase 3 studies for its mRNA based treatment targeting fibrosis
March 2023 : Moderna has revealed its intentions to construct a production plant in the United Kingdom as part of its efforts to enhance its manufacturing capabilities
January 2023 : The collaboration between Pfizer and BioNTech aims to increase the manufacturing of mRNA vaccines for new strains of COVID-19
Impact of Industry Transitions on the mRNA Synthesis & Manufacturing Market
As a core segment of the Biotechnology industry,
the mRNA Synthesis & Manufacturing market develops in line with broader industry shifts.
Over recent years, transitions such as Precision Medicine and Bio-Manufacturing Automation have redefined priorities
across the Biotechnology sector,
influencing how the mRNA Synthesis & Manufacturing market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Precision Medicine
The move towards precision medicine is changing mRNA applications significantly. This is especially evident in the fields of cancer treatment and gene therapies where personalized treatments are becoming more common This industry transition is expected to add $85 million in the industry revenue between 2024 and 2030.
02
Bio-Manufacturing Automation
The latest developments in bio-manufacturing automation are making the production of therapeutics efficient and cost effective. Additionally enhancing scalability throughout the sector